Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
EMERYVILLE, Calif., Oct. 31, 2016 -- Biossance™, the consumer beauty brand from Amyris, Inc. (NASDAQ:AMRS), today announced its planned launch in Sephora’s retail stores where the brand’s expansive line of high-performance skin care products will be available to consumers. The rollout to initial participating stores will begin in February 2017 and coincide with launching on Sephora online. Additional in-store and online marketing activities with Sephora to highlight the Biossance brand shortly following launch are planned.
“We are excited to launch with Sephora in the coming months and look forward to a strong partnership with them in the years to come. We expect this partnership combined with our strong growth will more than double our revenue in 2017,” said Caroline Hadfield, Senior Vice President, Personal Care, at Amyris. “Amyris and Sephora share similar philosophies when it comes to innovation, sustainability, and responsibility while providing efficacious products and we are delighted by their support of our brand.”
Sephora is the leading specialty beauty retailer globally, teaching and inspiring clients to play in a world of beauty. Sephora has earned its reputation with its expertise, innovation, and entrepreneurial spirit, and has been changing the face of prestige cosmetics since its debut in Paris in the early 1970’s. Now with more than 2,300 stores in 33 countries - including more than 500 stores across North America - plus an award-winning website and an intuitive mobile app, clients have the opportunity to discover 14,000 products from 200 carefully curated brands anytime, anywhere, anyhow.
About Biossance
Biossance uses innovative biotechnology to create skincare products that are incredibly effective, sustainable and safe. In its Berkeley-born labs 100% plant-based squalane was created sustainably from sugarcane. Biossance formulates with a No Compromise™ approach, proudly blacklisting over 2,000 ingredients that are potentially harmful to you or the planet. Pioneering sustainable beauty through biotechnology, Biossance makes sure only the most trustworthy and powerful ingredients make the final cut. The full Biossance skin care and beauty collection can be found at www.Biossance.com.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the company’s projection that the partnership combined with Amyris’s strong growth will more than double revenue in 2017) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 9, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, and Biossance are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
Media Contacts Elle Communications Megan Noller +1 (424)634-8370 [email protected] Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]
